



AUSTRALIA
Biotech
Invest 2016

Connecting Capital with Innovation

www.australiabiotechinvest.com.au

26 -27
October
2016

Host Industry Body Host State Partner Major Partner

AusBiotech
AUSTRALIAN BIOTECHNOLOGY ASSOCIATION

MELBOURNE
Victoria
Australia

100
csl
The global standard

Melbourne Convention
Centre, Victoria, Australia

Provectus Biopharmaceuticals, Inc.

WHEN PATIENTS WIN, WE ALL WIN™

Provectus Biopharmaceuticals, Inc. is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus' investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com or contact Porter, LeVay & Rose, Inc.